{"organizations": [], "uuid": "4e71c0aaea2b638672217824f5b6aa048ab10748", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-asterias-biotherapeutics-reports-m/brief-asterias-biotherapeutics-reports-milestone-targets-for-2018-idUSFWN1OZ0N0", "country": "US", "domain_rank": 408, "title": "BRIEF-Asterias Biotherapeutics Reports Milestone Targets For 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T19:42:00.000+02:00", "replies_count": 0, "uuid": "4e71c0aaea2b638672217824f5b6aa048ab10748"}, "author": "", "url": "https://www.reuters.com/article/brief-asterias-biotherapeutics-reports-m/brief-asterias-biotherapeutics-reports-milestone-targets-for-2018-idUSFWN1OZ0N0", "ord_in_thread": 0, "title": "BRIEF-Asterias Biotherapeutics Reports Milestone Targets For 2018", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-asterias biotherapeutics", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "asterias biotherapeutics inc", "sentiment": "none"}, {"name": "asterias biotherapeutics", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 5:42 PM / in 8 minutes BRIEF-Asterias Biotherapeutics Reports Milestone Targets For 2018 Reuters Staff 1 Min Read \nJan 4 (Reuters) - Asterias Biotherapeutics Inc: \n* ASTERIAS BIOTHERAPEUTICS INC - AS OF DECEMBER 31, 2017, ASTERIASâ€™ CASH AND CASH EQUIVALENTS TOTALED APPROXIMATELY $21.6 MILLION \n* ASTERIAS BIOTHERAPEUTICS SAYS INTENDS TO CONTINUE DISCUSSIONS WITH FDA TO ACHIEVE CLEARANCE ON DESIGN OF NEXT STUDY FOR AST-OPC1 \n* ASTERIAS BIOTHERAPEUTICS SAYS HAS SUFFICIENT RESOURCES TO FUND OPERATIONS THROUGH MID-2019 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T19:42:00.000+02:00", "crawled": "2018-01-04T20:06:43.020+02:00", "highlightTitle": ""}